LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Inicio・Lista de Acciones・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Cerrado

Sector Salud

252.42 2.45

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

245.29

Máximo

255.22

Métricas clave
By Trading Economics
Ingresos	49M -17M
Ventas	165M 660M
BPA	0.56
Margen de beneficio	-2.56
Empleados	2,100
EBITDA	50M 47M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+23.86 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-2.5B 33B
Apertura anterior	249.97
Cierre anterior	252.42

Noticias sobre sentimiento de mercado

By Acuity

50%

100 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

N/A / 280 Soporte y Resistencia

Alnylam Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2024, 23:42 UTC

Ganancias

Syrah Resources: Vidalia AAM Facility Has Ramped Up Operations

8 sept 2024, 23:41 UTC

Ganancias

Syrah Resources: No Natural Graphite Shipments in Half-Year to Chinese Anode Customers Amid Competition, Oversupply

8 sept 2024, 23:40 UTC

Ganancias

Syrah Resources: Half-Year Balama Production and Sales Decreased Compared With Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Revenue US$19 Mln Vs US$28.4 Mln in Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Comprehensive Loss US$63.3 Mln Vs US$37.1 Mln Loss in Prior Period

8 sept 2024, 22:38 UTC

Principales Noticias

Stocks Are Poised to Fall -- Barrons.com

8 sept 2024, 18:40 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- Update

8 sept 2024, 15:24 UTC

Principales Noticias

Boeing Reaches Deal With Biggest Union in Effort to Avoid Strike -- WSJ

8 sept 2024, 13:00 UTC

Principales Noticias

Crypto Plan Creates Potential Conflicts for Trump -- WSJ

8 sept 2024, 09:00 UTC

Principales Noticias

Nvidia Draws Antitrust Scrutiny as Enforcers Signal Early Interest in AI -- WSJ

8 sept 2024, 07:30 UTC

Principales Noticias

Biotechs Are in Focus as Congress Looks to Get Tougher on China -- Barrons.com

8 sept 2024, 01:00 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- WSJ

7 sept 2024, 17:35 UTC

Principales Noticias

Fed Outlook Remains Uncertain After September Cut -- Barrons.com

7 sept 2024, 09:30 UTC

Principales Noticias

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- Heard on the Street -- WSJ

7 sept 2024, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 sept 2024, 04:05 UTC

Principales Noticias

China's Forex Reserves Rose in August as U.S. Dollar Weakened -- WSJ

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

Comparación entre iguales

Cambio de precio

Alnylam Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

23.86% repunte

Estimación a 12 meses

Media 305.67 USD 23.86%

Máximo 400 USD

Mínimo 233 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alnylam Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

22 ratings

Comprar

Mantener

Vender

De acuerdo con 22 analistas que ofrecen calificaciones bursátiles a para Alnylam Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 280Soporte y Resistencia

All events are bearish.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

100 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.